CASE COMMENTS: MERGERS – RELEVANT MARKET – COMMITMENTS – PHARMACEUTICAL AND GENERIC PRODUCTS

Relevant Market – Commitments : The European Commission refines its market definition for finished dose pharmaceuticals and clears an acquisition in this sector subject to commitments (Teva / Ratiopharm)

KEYWORDS
– Eur. comm., dec. art. 6(2) Reg. 139/2004, 3 August 2010, Teva/Ratiopharm, case COMP/M.5865 On 3 August 2010, the European Commission cleared, subject to conditions and obligations, the acquisition by Teva Pharmaceutical Industries Limited («Teva») of Merckle GmbH, CT Arzneimittel GmbH and AbZ-Pharma GmbH (collectively, «Ratiopharm»). Teva is an international pharmaceutical company based in Israel and is involved in the development, production and marketing of proprietary and generic pharmaceutical products as well as biopharmaceuticals and active pharmaceutical ingredients. Ratiopharm is an international pharmaceutical company based in Germany that is active in generic products and biopharmaceuticals. The Commission's investigation found that competition concerns could be excluded in

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

This document is protected by copyright laws and international copyright treaties. Non-authorised use of this document constitutes a violation of the publisher's rights and may be punished by up to 3 years imprisonment and up to a € 300 000 fine (Art. L 335-2 Code de la Propriété Intellectuelle). Personal use of this document is authorised within the limits of Art. L 122-5 CPI and DRM protection.